LONDON, April 14 /PRNewswire/ -- Chiltern, a leading global research organization, announced that it has opened a new office in St. Petersburg, Russia following the recent appointment of Dr. Alexey V. Kornilov as General Manager of its Russian operations.
This office is expected to grow rapidly under the leadership of Alexey V. Kornilov, MD and will be primarily focused on supporting our Global Clinical Development brand. Dr. Kornilov brings over 10 years of clinical experience to Chiltern and is a member of the St. Petersburg Society of Anesthesiology.
Over the last few years, Chiltern has conducted many trials in Russia to fulfill sponsors' demands in the region and to take advantage of highly qualified investigator sites generating high quality data.
"The opening of our St. Petersburg office is a logical next step in Chiltern's continued growth in Central & Eastern Europe," commented Armand Czaplinski MD, MBA, Chiltern General Manager, CEE. "Today, with an ever higher number of competing trials, the pharmaceutical industry increasingly recognizes the potential of CEE countries to meet enrollment goals. The availability of trained staff and the quality of the data produced, has resulted in an increased number of FDA and EMEA approved clinical trials."
Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad
therapeutic range for a wide variety of clients. Chiltern employs more than
1,200 people with 20 offices across the United States, Europe and in India.
Chiltern provides services including Early Phase, Global Clinical
Development, Late Phase, Biometrics, Medical and Regulatory Affairs and
For More Information Contact:
Catherine Lemercier Richard Baptista
Chiltern International, Inc. Chiltern International Ltd.
2111 Palomar Airport Road 171 Bath Road
Suite 200 Slough
CA 92011 SL1 4AA
USA UNITED KINGDOM
Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000
Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116
Copyright©2008 PR Newswire.
All rights reserved